Tatva Chintan Pharma Chem Limited — PPTs, 16-05-2026: Investor Presentation

Tatva Chintan Pharma Chem delivered strong performance for the latest quarter and full fiscal year. Full-year revenue from operations increased 32% to ₹505.9 Cr, with profit after tax (PAT) surging 636% to ₹42.1 Cr. For the latest quarter, revenue grew 24% to ₹134.1 Cr, and PAT soared 902% to ₹10.3 Cr. Structure Directing Agents (SDA) and Pharma & Agrochemical Intermediates (PASC) were major revenue contributors.

The company is strategically focused on niche specialty chemicals, utilizing in-house R&D and green chemistry processes like electrolysis and continuous flow chemistry. Capacity expansion at its Dahej SEZ facility, now with a combined installed reactor capacity of 791 KL and 39 assembly lines, is set to boost future revenues.

Full-year EPS climbed to ₹17.98 from ₹2.44, and quarterly EPS reached ₹4.41 from ₹0.44 year-on-year. EBITDA margin for the full year significantly improved to 18% from 9%, reflecting enhanced profitability.

The industry outlook for Indian specialty chemical manufacturers remains positive, driven by the 'China+1' strategy and a global shift towards sustainable product development, presenting substantial growth opportunities.